clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Fibrosis D005355 23 associated lipids
Fistula D005402 8 associated lipids
Foot Diseases D005534 4 associated lipids
Fractures, Open D005597 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Gastritis D005756 27 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Zhou L et al. Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. 2016 Helicobacter pmid:26104022
Watanabe M et al. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal. 2016 Int J Pharm pmid:27553780
Nagashima A et al. Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. 2016 Antimicrob. Agents Chemother. pmid:27550358
Couture G et al. [Second case of serum sickness-like reaction to claritrhomycin]. 2016 Presse Med pmid:27542759
Bugli F et al. In vitro effect of clarithromycin and alginate lyase against helicobacter pylori biofilm. 2016 Biotechnol. Prog. pmid:27535356
Abd-Elsalam S et al. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. 2016 Medicine (Baltimore) pmid:27310977
De Francesco V et al. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication. 2016 J Gastrointestin Liver Dis pmid:27308644
Miyaki A et al. An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility. 2016 Minerva Gastroenterol Dietol pmid:27304198
Kim JS et al. Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial. 2016 Gut Liver pmid:27114421
Manniello MD et al. Aerodynamic properties, solubility and in vitro antibacterial efficacy of dry powders prepared by spray drying: Clarithromycin versus its hydrochloride salt. 2016 Eur J Pharm Biopharm pmid:27106605
Fallone CA et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. 2016 Gastroenterology pmid:27102658
Bilgilier C et al. Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients. 2016 Ann. Hematol. pmid:27091350
Murakami K et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. 2016 Gut pmid:26935876
Park JY et al. Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. 2016 Dig. Dis. Sci. pmid:26923948
Guirao-Arrabal E et al. Clarithromycin plus linezolid as a sequential therapy for implantable-cardioverter-defibrillator infection caused by coagulase-negative staphylococci. 2016 Rev Esp Quimioter pmid:26888341
Trac MH et al. Macrolide antibiotics and the risk of ventricular arrhythmia in older adults. 2016 CMAJ pmid:26903359
Mukai S et al. Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines. 2016 Int. J. Oncol. pmid:26718641
Hirama T et al. PCR-Based Rapid Identification System Using Bridged Nucleic Acids for Detection of Clarithromycin-Resistant Mycobacterium avium-M. intracellulare Complex Isolates. 2016 J. Clin. Microbiol. pmid:26739154
Radheshi E et al. Postmortem diagnosis of anaphylaxis in presence of decompositional changes. 2016 J Forensic Leg Med pmid:26735898
Hassan ST et al. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. 2016 Pharm Biol pmid:26731378
Hollitt A et al. Cat scratch disease of the parotid gland. 2016 Arch. Dis. Child. pmid:26403943
Oh B et al. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. 2016 Helicobacter pmid:26395781
Graham DY and Gisbert JP Letter: clarithromycin dose for H. pylori therapy remains unresolved. 2015 Aliment. Pharmacol. Ther. pmid:26238583
Navarro-Jarabo JM et al. Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain. 2015 Digestion pmid:26227669
Ufuk A et al. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. 2015 Pharm. Res. pmid:26224396
Jeong BH et al. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. 2015 Am. J. Respir. Crit. Care Med. pmid:25393520
Yu T et al. Study on clarithromycin lactobionate based dual selector systems for the enantioseparation of basic drugs in capillary electrophoresis. 2015 J Sep Sci pmid:26097042
Trotti LM et al. Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial. 2015 Ann. Neurol. pmid:26094838
Tai WC et al. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication. 2015 Biomed Res Int pmid:26090428
Nguyen AT et al. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections. 2015 Cornea pmid:26075451
AktaÅŸ B et al. The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies. 2015 Eur J Gastroenterol Hepatol pmid:25919773
Townsell MY et al. Pathology in practice. Canine distemper virus disease in a dog. 2015 J. Am. Vet. Med. Assoc. pmid:25719842
Scherübl H et al. [What is new in treating Helicobacter pylori infection?]. 2015 Dtsch. Med. Wochenschr. pmid:25704525
Aoki H et al. Clarithromycin highly-loaded gastro-floating fine granules prepared by high-shear melt granulation can enhance the efficacy of Helicobacter pylori eradication. 2015 Eur J Pharm Biopharm pmid:25703356
Baysal B et al. Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients. 2015 Turk J Gastroenterol pmid:25698264
Blix HS et al. Antibiotic prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveillance? 2015 Epidemiol. Infect. pmid:25388750
Amiri M Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura. 2015 Glob J Health Sci pmid:26925898
Haghi M et al. Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. 2015 Pharm. Res. pmid:25537341
Li DQ et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. 2015 CMAJ pmid:25534598
Montes M et al. Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response. 2015 Helicobacter pmid:25382231
Park JB et al. Modulation of microenvironmental pH and utilization of alkalizers in crystalline solid dispersion for enhanced solubility and stability of clarithromicin. 2015 Arch. Pharm. Res. pmid:25213008
Anton E et al. Randomized Trial of Clarithromycin for Mediterranean Spotted Fever. 2015 Antimicrob. Agents Chemother. pmid:26711765
Winters N et al. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. 2015 Eur. Respir. J. pmid:26381514
Parra D et al. In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions. 2015 BMC Microbiol. pmid:26518881
Xing J et al. The application of high-resolution mass spectrometry-based data-mining tools in tandem to metabolite profiling of a triple drug combination in humans. 2015 Anal. Chim. Acta pmid:26515003
Demirci H et al. Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection. 2015 Turk J Gastroenterol pmid:26510082
Bérard A et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. 2015 Pharmacoepidemiol Drug Saf pmid:26513406
Agrawal V et al. A Case of Hypotension and Bradycardia Precipitated by Drug Interaction of Clarithromycin and Calcium-Channel Blocker. 2015 J Am Geriatr Soc pmid:26389998
Glocker EO The Need for Resistance Surveillance and Antimicrobial Susceptibility Testing of Helicobacter pylori. 2015 Digestion pmid:26372776